Bingham Private Wealth LLC Makes New $495,000 Investment in Amgen Inc. $AMGN

Bingham Private Wealth LLC bought a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,511 shares of the medical research company’s stock, valued at approximately $495,000.

Other hedge funds have also modified their holdings of the company. Board of the Pension Protection Fund acquired a new position in shares of Amgen in the 4th quarter worth approximately $26,000. Olistico Wealth LLC acquired a new position in shares of Amgen in the 4th quarter worth approximately $33,000. Holos Integrated Wealth LLC acquired a new position in shares of Amgen in the 4th quarter worth approximately $37,000. Cloud Capital Management LLC acquired a new position in shares of Amgen in the 3rd quarter worth approximately $34,000. Finally, Saranac Partners Ltd acquired a new position in shares of Amgen in the 3rd quarter worth approximately $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on AMGN. Truist Financial increased their target price on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. Leerink Partners reissued a “market perform” rating and issued a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. Deutsche Bank Aktiengesellschaft increased their target price on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Citigroup increased their target price on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $356.24.

Amgen Trading Up 0.3%

AMGN stock opened at $350.95 on Wednesday. The business has a fifty day moving average price of $364.22 and a 200 day moving average price of $336.58. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The stock has a market capitalization of $189.40 billion, a price-to-earnings ratio of 24.66, a P/E/G ratio of 3.29 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the firm posted $5.31 EPS. The business’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.